| Document |
Document Title |
|
WO/1998/000405A1 |
A method of preventing, treating, terminating and protecting against cardiac arrhythmias, such as atrial, supraventricular and ventricular ectopy, tachycardia, flutter or fibrillation, including atrial, supraventricular and ventricular a...
|
|
WO/1998/000427A1 |
The present invention discloses new processes in the preparation of midazolam (VII), a commercially important pharmaceutical, as well as new intermediates in those processes from a known benzophenone (I) starting material.
|
|
WO/1998/000406A1 |
The invention is directed to a method useful in the treatment of preterm labor, dysmenorrhea and for the stoppage of labor preparatory to cesarean delivery.
|
|
WO/1997/049690A1 |
A method for the treatment of Meniere's disease comprising the administration of a medicament which modulates the IKs channel of the ear and thereby reduces endolymph production.
|
|
WO/1997/048686A1 |
This invention is concerned with novel compounds represented by structural formula (I) which are useful in the treatment of arrhythmia.
|
|
WO/1997/047625A1 |
Tricyclic compounds of general formula (I) as defined herein which exhibit antagonist activity at V1 and/or V2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases character...
|
|
WO/1997/044334A2 |
The invention refers to novel piperazine and homopiperazine derivatives of formula (I) being suitable for the treatment of dieseases due to pathological alterations of the central nervous system, pharmaceutical compositions containing th...
|
|
WO/1997/044329A1 |
Cyclic diamines of formula (I) or their pharmacologically acceptable acid addition salts, and their medical applications are described. These compounds inhibit the action of chemokines such as MIP-la and/or MCP-l on target cells, and are...
|
|
WO/1997/043239A1 |
Matrix metalloprotease inhibiting compounds, pharmaceutical compositions thereof and a method of disease treatment using such compounds are presented. The compounds of the invention have generalized formula (1) wherein r is 0-2, T is sel...
|
|
WO/1997/040023A1 |
The present invention relates to novel compounds of general formula (I) which can be used for treating medical disorders resulting from a deficiency in growth hormone.
|
|
WO/1997/038984A1 |
The present application describes N-(amidinophenyl) cyclourea analogs of formula (I) which are useful as inhibitors of factor Xa.
|
|
WO/1997/036879A1 |
The present invention is directed to substituted benzodiazepine compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic composi...
|
|
WO/1997/034878A1 |
The invention relates to substituted 2,3-benzodiazepin-4-ones which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and f...
|
|
WO/1997/035198A1 |
The present invention relates to a method useful in combinatorial chemistry. More specifically, the present invention relates to methods for synthesizing spatially-dispersed positionally-encoded combinatorial chemistry libraries of oligo...
|
|
WO/1997/032865A1 |
The invention relates to novel aryl glycinamide derivatives of formula (I) and their pharmaceutically acceptable salts, in which R1 and R2 together with the N to which they are bound form a ring of one of the formulae (a), (b), (c) or (d...
|
|
WO/1997/030992A1 |
This invention relates to compounds that inhibit farnesyl-protein transferase and ras protein farnesylation, thereby making them useful as anti-cancer agents. The compounds are also useful in the treatment of diseases, other than cancer,...
|
|
WO/1997/028135A1 |
The invention concerns compounds of formula (I), in which: X designates hydrogen or halogen; Y designates -NR3- or -N=; R1, R2 and R3 designate hydrogen or different substituents; R4 designates optionally substituted C1-C6 alkyl; R5 desi...
|
|
WO/1997/028163A1 |
The invention concerns compounds of formula (I), in which R1, R2, R3 and R4 mean hydrogen or different substituents; X means hydrogen or halogen; Y means C1-6 alkoxy or X and Y together mean -O-(CH2)n-O-; n means 1, 2 or 3; and A togethe...
|
|
WO/1997/028141A1 |
Compounds of formula (I), wherein R1 is hydrogen or straight or branched C1-6 alkyl, Z2 is O, NH, CH2O or CH2NH, each of R2 and R3, which are the same or different, is hydrogen or a group selected from straight or branched alkyl, alkoxy,...
|
|
WO/1997/025324A1 |
The present invention concerns aza- and diazacycloheptane and cyclooctane compounds from the following formula (I) Ar1-A-B-Ar2 wherein Ar1, A, B, and Ar2 have the meanings given in the description. The compounds according to the inventio...
|
|
WO/1997/024336A2 |
A new process for preparing substituted 7-aminocarbonyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepi
nes is disclosed.
|
|
WO/1997/024119A1 |
Compounds of formulae (I-V) are disclosed which are vitronectin receptor antagonists and are useful in the treatment of osteoporosis.
|
|
WO/1997/023467A1 |
Compounds of formula (I) as well as their pharmaceutically acceptable salts, and pharmaceutical compositions comprising the novel compounds. The novel compounds of formula (I) are useful in the management of pain.
|
|
WO/1997/023202A1 |
The invention relates to subtype-selective NMDA receptor ligands and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative d...
|
|
WO/1997/022619A2 |
The present invention relates to novel classes of compounds which are inhibitors of interleukin-1'beta' converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This i...
|
|
WO/1997/021685A1 |
A compound of formula (I) is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.
|
|
WO/1997/017344A1 |
There are provided novel compounds of formula (I), wherein X, R1, R2, R3, R4 and R5 are as defined in the specification and optical isomers and racemates thereof and pharmaceutically acceptable salts thereof; together with processes for ...
|
|
WO/1997/016430A1 |
Disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders, including neurodegenerative disorders, di...
|
|
WO/1997/011061A1 |
Compounds represented by general formula (I) or (II) or salts thereof which are useful as a retinoid potentiator, wherein R1 represents hydrogen or C1-6 alkyl; R2 and R3 represent each hydrogen or C1-6 alkyl, or R2 and R3 together form 5...
|
|
WO/1997/005129A1 |
The compound represented by formula (I) and physiologically acceptable acid-addition salts thereof. The compounds have an excellent antiemetic effect based on potent antagonism against serotonin S3 and dopamine D2 receptors and, therefor...
|
|
WO/1997/001349A1 |
A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.
|
|
WO/1997/001560A1 |
A method has now been found of synthesizing a combinatorial library of 1,4-benzodiazepin-2,5-diones on solid supports via an aza-Wittig ring closure, said compounds optionally encoded with tags, and to the use of this library in assays t...
|
|
WO/1996/041795A1 |
This invention relates to new benzamide derivatives having a vasopressin antagonistic activity, etc., and represented by general formula (I), wherein R1 is aryl optionally substituted with lower alkoxy, etc., R2 is lower alkyl, etc., R3 ...
|
|
WO/1996/040663A1 |
The present invention relates to compounds, compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises a di- or tri-aminoguanidine of formula (I), capable o...
|
|
WO/1996/040146A1 |
This invention is concerned with novel compounds represented by structural formula (I) which are useful in the treatment of arrhythmia.
|
|
WO/1996/040656A1 |
This invention is concerned with novel compounds represented by structural formula (I), which are useful in the treatment of arrhythmia.
|
|
WO/1996/040652A1 |
The present invention relates generally to methods for the preparation of unsymmetrically substituted cyclic ureas of formulae (VIa) and (VIb), which are useful as HIV protease inhibitors. The methods provided go through an isourea inter...
|
|
WO/1996/040653A1 |
This invention is concerned with novel compounds represented by structural formula (I) which are useful in the treatment of arrhythmia.
|
|
WO/1996/040202A1 |
A solid-phase method for the synthesis of N-substituted oligomers, such as poly (N-substituted glycines) (referred to herein as poly NSGs) is used to obtain oligomers, such as poly NSGs of potential therapeutic interest which poly NSGs c...
|
|
WO/1996/040655A1 |
This invention is concerned with novel compounds represented by structural formula (I) which are useful in the treatment of arrhythmia.
|
|
WO/1996/040654A1 |
This invention is concerned with novel compounds represented by structural formula (I) which are useful in the treatment of arrhythmia.
|
|
WO/1996/039393A1 |
Disubstituted cyclic ureas IV are prepared by reductive alkylation of I with aldehydes R22-CHO or R23-CHO in presence of a reducing agent to form II (step 1), followed by cyclocarbonylation of II to form III (step2) and deprotection of I...
|
|
WO/1996/038421A1 |
N,N-di(aryl)cyclic urea derivatives, such as the compounds of formula (III) wherein R1 is -C(NH)NH2, -C(NH)N(H)OR11, -C(NH)N(H)C(O)R9, or -C(NH)N(H)C(O)OR11; R2 and R3 are independently hydrogen, halo, lower alkyl, lower haloalkyl, aryl,...
|
|
WO/1996/038422A1 |
Fused benzodiazepinone derivatives represented by general formula (I) or salts thereof which have medicinal effects,in particular, preventive or therapeutic effects on heart diseases in which muscarine M2 receptors participate, wherein X...
|
|
WO/1996/037465A1 |
The invention relates to a chiral compound of general formula (I), wherein the groups R are the same or different but preferentially the same and are aliphatic C1-10 groups or optionally substituted aromatic groups or that both groups R ...
|
|
WO/1996/035677A1 |
Compounds having formula (I) wherein R1, R5, R6 and R7 are hydrogen or certain specified substituents; R8 and R9 are independently hydrogen, hydroxy or alkoxy; and X, A and B are independently NR2, O, S, SO, SO2, CH=CH or (CH2)p, p being...
|
|
WO/1996/034856A1 |
This invention is concerned with 2-ureido-benzamide compounds of formula (1), in which R1 is H, halogen, alkyl, alkoxy or dialkylamino and R2 is H, halogen, hydroxy, nitro, alkyl, alkoxy, cycloalkylmethoxy, alkylthio, alkylsulfinyl, alky...
|
|
WO/1996/033723A2 |
This invention relates to use of a compound of formula (I) wherein each symbol is as defined in the description, or its pharmaceutically accpetable salt, for treating and/or preventing Meniere's syndrome or motion sickness.
|
|
WO/1996/031473A1 |
A compound of formula (I), in which Z is selected from (a), (b), (c), (d), (e), (f), (g), (h), (i), (j) and (k). The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substitu...
|
|
WO/1996/031474A1 |
A compound of formula (I), in which Z is selected from (a), (b), (c), (d), (e), (f), (g), (h), (i), (j) and (k). The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substitu...
|
